演題抄録

ポスター

開催概要
開催回
第56回・2018年・横浜
 

切除不能な進行再発大腸癌に対してアフリベルセプトを使用した23症例の検討

演題番号 : P18-7

[筆頭演者]
演者)山田 和之介:1 
[共同演者]
鈴木 雅貴:1、小澤 大悟:1、小川 敦:1、持田 泰:1、深井 康幸:1、尾嶋 仁:1

1:群馬県立がんセンター・消化器外科

 

We report the experience of using the novel antiangiogenic agent aflibercept to FOLFIRI in patients with unresectable colorectal cancer.
Methods: 23 patients with unresectable colorectal cancer were used the aflibercept from July 2017 to April 2018. We examined response rate and adverse events.
Results: Median age was 65(37-77) years. Four (17.4%) tumors were located in the cecum, one (4.3%) was in the transverse colon and descending colon respectively, three (13.0%) were in the Sigmoid colon, ten (43.4%) were in the upper rectum and four (17.4%) were in the lower rectum. Pathological findings are as follows: the well and moderately differentiated type (87.0%) was the most common histological type, followed by mucinous (8.7%) and poorly differentiated adenocarcinoma (4.3%). 15 cases (65.0%) had a KRAS mutation. The primary resection was performed in 17 cases (73.9%), of which Cur A was 10 cases. 3 (13.0%) patients received the aflibercept in 2nd line, 11 (47.8%) in 3rd line, 6 (26.1%) in 4th line and 3 (13.0%) in 5th line. Objective response rate was 17.4%. The most common treatment-emergent adverse events leading to discontinuation of any treatment component were proteinuria (5, 21.7%) and myelosuppression (4, 17.4%), but hypertension did not occur. The appearance timing of proteinuria was 3 (1-8) courses. The incidence of grade 3 or worse treatment-emergent adverse events was 17.4% (gastrointestinal perforation 4.3%, myelosuppression 8.7%, heart failure 4.3%). Most adverse events could be managed by supportive cares or dose changes, while one case also required emergency surgery with gastrointestinal perforation.
Conclusion: Safety use and therapeutic effect in some cases were confirmed, however, serious complications may occur. Careful observation is necessary in the treatment.

キーワード

臓器別:大腸・小腸

手法別:化学療法

前へ戻る